AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18515448 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine
Number of subjects: 28
Study 15733932 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (5-HTP; 4 mg/kg in non enteric-coated tablets)
Number of subjects: 18
Study 15733932 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 matched healthy volunteers)
Number of subjects: 18
Study 12837810 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (GemVin)
Number of subjects: 501
Study 12837810 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-based regimens (gemcitabine plus cisplatin or vinorelbine plus cisplatin)
Number of subjects: 501
Study 10349695 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2b (rIFN-alpha 2b) plus oral ribavirin (1,000 or 1,200 mg)
Number of subjects: 0
Study 10349695 — intervention group
Group type: COMPARATOR
Intervention: Recombinant interferon alfa-2b (rIFN-alpha 2b) monotherapy
Number of subjects: 0
Study 10349695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (rIFN-alpha 2b alone and combination therapy)
Number of subjects: 0
Study 7503040 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrothermal debonding (ETD)
Number of subjects: 10
Study 7503040 — intervention group
Group type: COMPARATOR
Intervention: Conventional debonding method (pliers)
Number of subjects: 10
Study 1772105 — intervention group
Group type: EXPERIMENTAL
Intervention: RU41740 (2 mg daily for one week in the first month, 1 mg daily for one week in the second month)
Number of subjects: 12
Study 1772105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7075104 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg Digoxin + Placebo (PL2)
Number of subjects: 6
Study 7075104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg Digoxin + Quinidine (Q)
Number of subjects: 6
Study 7075104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg Digoxin
Number of subjects: 6
Study 7075104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg Digoxin + Sparteine (SP)
Number of subjects: 6
Study 30790694 — intervention group
Group type: EXPERIMENTAL
Intervention: AED applied
Number of subjects: 2809
Study 30790694 — intervention group
Group type: COMPARATOR
Intervention: No AED applied
Number of subjects: 2809
Study 26053465 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS inserted at the time of CS
Number of subjects: 48
Study 26053465 — intervention group
Group type: COMPARATOR
Intervention: Control group (LNG-IUS inserted at six weeks postpartum)
Number of subjects: 48
Study 24863486 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA-TT vaccine (Meningococcal group A polysaccharide conjugated to tetanus toxoid)
Number of subjects: 0
Study 24863486 — intervention group
Group type: COMPARATOR
Intervention: Mencevax ACWY (quadrivalent plain polysaccharide vaccine)
Number of subjects: 0
Study 22277697 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated 2% lignocaine
Number of subjects: 32
Study 22277697 — intervention group
Group type: COMPARATOR
Intervention: 18% benzocaine/2% tetracaine gel
Number of subjects: 32
Study 18326529 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning (EL)
Number of subjects: 40
Study 18326529 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruction (CI)
Number of subjects: 40
Study 17329509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.87 g/d E2 gel
Number of subjects: 442
Study 17329509 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g/d E2 gel
Number of subjects: 442
Study 17329509 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6 g/d E2 gel
Number of subjects: 442
Study 17329509 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 442
Study 15215483 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate therapy (1 mg of folic acid, 5 mg of vitamin B6, and 1 mg of vitamin B12 intravenously, followed by daily oral doses of 1.2 mg of folic acid, 48 mg of vitamin B6, and 60 microg of vitamin B12 for six months)
Number of subjects: 636
Study 15215483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636
Study 15215483 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate therapy
Number of subjects: 636
Study 11862564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic drainage
Number of subjects: 59
Study 11862564 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 59
Study 9509065 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg orally for 4 days at 1700 hours
Number of subjects: 10
Study 9509065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7876491 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct electrical nerve stimulation
Number of subjects: 24
Study 3177433 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO 150 unit/kg intravenously three times weekly
Number of subjects: 12
Study 3177433 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO 50 unit/kg intravenously three times weekly
Number of subjects: 12
Study 3177433 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO 100 unit/kg intravenously three times weekly
Number of subjects: 12
Study 3177433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3177433 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (all doses)
Number of subjects: 12
Study 3177433 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (open label)
Number of subjects: 12
Study 31693077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 251
Study 31693077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 251
Study 31693077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks
Number of subjects: 251
Study 31693077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 31693077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (both regimens)
Number of subjects: 251
Study 28329863 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle redesign intervention (n = 232)
Number of subjects: 460
Study 28329863 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (n = 228)
Number of subjects: 460
Study 27573325 — intervention group
Group type: EXPERIMENTAL
Intervention: i-SIDRA
Number of subjects: 200
Study 27573325 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methodology
Number of subjects: 200
Study 24388167 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib (IV, 50 mg/m2)
Number of subjects: 0
Study 24388167 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (oral, 150 mg)
Number of subjects: 0
Study 22486141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg tablets twice a day for one week)
Number of subjects: 40
Study 22486141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tablets with the same dosage as sildenafil)
Number of subjects: 40
Study 20398487 — intervention group
Group type: EXPERIMENTAL
Intervention: National-made ablation catheter (Group 1)
Number of subjects: 1342
Study 20398487 — intervention group
Group type: COMPARATOR
Intervention: Imported ablation catheter (Group 2)
Number of subjects: 1342
Study 18841079 — intervention group
Group type: EXPERIMENTAL
Intervention: Power scheme (8 sets of 6 repetitions at 45% of 1RM, 3-minute rest periods, explosive and ballistic movements)
Number of subjects: 11
Study 18841079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy scheme (10 sets of 10 repetitions at 75% of 1RM, 2-minute rest periods, controlled movements)
Number of subjects: 11
Study 18841079 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength scheme (6 sets of 4 repetitions at 88% of 1RM, 4-minute rest periods, explosive intent)
Number of subjects: 11
Study 16085339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid total-tau (tau)
Number of subjects: 219
Study 16085339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid phosphorylated-tau181 (p-tau181)
Number of subjects: 219
Study 16085339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid tau/Abeta42 ratio
Number of subjects: 219
Study 16085339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid phospho-tau(181)/Abeta42 ratio
Number of subjects: 219
Study 16085339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid tau
Number of subjects: 219
Study 16085339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid p-tau(181)
Number of subjects: 219
Study 16085339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid p-tau181
Number of subjects: 219
Study 16085339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid p-tau181/Abeta42 ratio
Number of subjects: 219
Study 12678357 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 100
Study 12678357 — intervention group
Group type: COMPARATOR
Intervention: Mosaicplasty
Number of subjects: 100
Study 10640840 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% 5-fluorouracil in Belanyx vehicle
Number of subjects: 57
Study 10640840 — intervention group
Group type: COMPARATOR
Intervention: Belanyx vehicle
Number of subjects: 57
Study 8917247 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, 10 mg/kg per day, twice a day for 7 days
Number of subjects: 17
Study 8917247 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 10 mg/kg per day, once a day for 5 days
Number of subjects: 17
Study 8917247 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (historical control)
Number of subjects: 17
Study 1899732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroid treatment (0.5 g solumedrol) before or at the same time as the first OKT3 injection
Number of subjects: 27
Study 1899732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroid treatment (0.5 g solumedrol) before the first OKT3 injection
Number of subjects: 27
Study 7040581 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg oral dose
Number of subjects: 10
Study 7040581 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 240 mg/day
Number of subjects: 10
Study 7040581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30889566 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Tremor (ET) prevalence assessment
Number of subjects: 1328
Study 30541152 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal use education
Number of subjects: 70
Study 30541152 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 26716866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg kg(‐1) loading dose over 10 min followed by 0.5 μg kg(‐1) h(‐1) during one-lung ventilation)
Number of subjects: 50
Study 26716866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 50
Study 26716866 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 50
Study 25325116 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept added to Folfiri protocol
Number of subjects: 1226
Study 25325116 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1226
Study 25325116 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 1226
Study 22627919 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower abdomen
Number of subjects: 4
Study 22627919 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper abdomen
Number of subjects: 4
Study 20226443 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplementation
Number of subjects: 56
Study 20226443 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched women)
Number of subjects: 56
Study 17635426 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 100
Study 17635426 — intervention group
Group type: COMPARATOR
Intervention: Facemask and oropharyngeal airway
Number of subjects: 100
Study 17635426 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 100
Study 16526415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary phytoestrogens (soy and unrefined grain products)
Number of subjects: 0
Study 16526415 — intervention group
Group type: COMPARATOR
Intervention: Various dietary patterns rich in phytoestrogens
Number of subjects: 0
Study 11981151 — intervention group
Group type: EXPERIMENTAL
Intervention: Clot Signature Analyzer collagen‐induced thrombus formation (CITF) assay
Number of subjects: 57
Study 11981151 — intervention group
Group type: EXPERIMENTAL
Intervention: Clot Signature Analyzer CITF
Number of subjects: 57
Study 10371877 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc citrate dentifrice (2% zinc citrate and 0.76% sodium monofluorophosphate in a silica base)
Number of subjects: 75
Study 10371877 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (0.76% sodium monofluorophosphate in a silica base)
Number of subjects: 75
Study 8584682 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluspirilene 0.5 mg per week
Number of subjects: 106
Study 8584682 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluspirilene 1.0 mg per week
Number of subjects: 106
Study 8584682 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluspirilene 1.5 mg per week
Number of subjects: 106
Study 8584682 — intervention group
Group type: EXPERIMENTAL
Intervention: Test therapy (initial response after 2 weeks)
Number of subjects: 106
Study 8584682 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreases in somatic anxiety, psychic anxiety, and Hamilton-total-score
Number of subjects: 106
Study 2093885 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 17
Study 2093885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 637427 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet (20 g of crude fiber)
Number of subjects: 8
Study 637427 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber diet (3 g of crude fiber)
Number of subjects: 8
Study 637427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 8
Study 31318075 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy with lenient definitions of remission
Number of subjects: 106
Study 31318075 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy with stringent definitions of remission
Number of subjects: 106
Study 31318075 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of 11 definitions of remission
Number of subjects: 106
Study 28914104 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (diet + exercise)
Number of subjects: 180
Study 25774836 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group clinic appointments
Number of subjects: 198
Study 25774836 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 198
Study 23923010 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tumors (positive ER protein expression and gene ratio normal or gain/amplification)
Number of subjects: 1010
Study 23923010 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel therapy
Number of subjects: 1010
Study 23923010 — intervention group
Group type: COMPARATOR
Intervention: Gene Functional profile
Number of subjects: 1010
Study 21568077 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine
Number of subjects: 27
Study 21568077 — intervention group
Group type: COMPARATOR
Intervention: 0.5% apraclonidine
Number of subjects: 27
Study 19458055 — intervention group
Group type: EXPERIMENTAL
Intervention: Satraplatin administered orally at 80 mg/m² once daily for 5 consecutive days every 5 weeks (fasted state)
Number of subjects: 17
Study 19458055 — intervention group
Group type: COMPARATOR
Intervention: Satraplatin administered in fed state on day 1 and day 5 of cycle 1
Number of subjects: 17
Study 19458055 — intervention group
Group type: EXPERIMENTAL
Intervention: Satraplatin administered in fasted state for subsequent cycles
Number of subjects: 17
Study 16751782 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 195
Study 16751782 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 195
Study 15641642 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute poisonings via ingestion
Number of subjects: 71589
Study 15641642 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute poisonings via dermal exposure
Number of subjects: 71589
Study 15641642 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute poisonings via inhalation
Number of subjects: 71589
Study 15641642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional poisoning
Number of subjects: 71589
Study 15641642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical poisons
Number of subjects: 71589
Study 15641642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical poisons
Number of subjects: 71589
Study 15641642 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural toxins
Number of subjects: 71589
Study 15641642 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal trends in poisonings
Number of subjects: 71589
Study 11391226 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day RAD
Number of subjects: 103
Study 11391226 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day RAD
Number of subjects: 103
Study 11391226 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day RAD
Number of subjects: 103
Study 9266292 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative physical treatment
Number of subjects: 136
Study 8104238 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol with moderate sodium restriction
Number of subjects: 19
Study 8104238 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol without sodium restriction
Number of subjects: 19
Study 2878953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg orally
Number of subjects: 20
Study 2878953 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 160 mg orally
Number of subjects: 20
Study 30114973 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric leg press training at S-MTU (knee angle 145°)
Number of subjects: 15
Study 30114973 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric leg press training at L-MTU (knee angle 85°)
Number of subjects: 15
Study 30114973 — intervention group
Group type: COMPARATOR
Intervention: Both training groups (S-MTU and L-MTU)
Number of subjects: 15
Study 29776410 — intervention group
Group type: EXPERIMENTAL
Intervention: Counsellor-supported disclosure model (CSD)
Number of subjects: 276
Study 29776410 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV testing & counselling (HTC)
Number of subjects: 276
Study 28868876 — intervention group
Group type: EXPERIMENTAL
Intervention: Quyu Huatan decoction
Number of subjects: 93
Study 28868876 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 93
Study 23674271 — intervention group
Group type: EXPERIMENTAL
Intervention: First Leaf (FL; composed of blackcurrant extract powder, lactoferrin and lutein)
Number of subjects: 30
Study 23674271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cassis Anthomix 30 (CAM30; blackcurrant extract powder)
Number of subjects: 30
Study 22545801 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention focusing on internalized heterosexism (IH) reduction
Number of subjects: 367
Study 22545801 — intervention group
Group type: COMPARATOR
Intervention: Control condition focusing on stress management
Number of subjects: 367
Study 20347079 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone vaginal gel
Number of subjects: 468
Study 20347079 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (IMP)
Number of subjects: 468
Study 18541303 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (0.59+/‐0.07 g/kg body weight)
Number of subjects: 13
Study 18541303 — intervention group
Group type: COMPARATOR
Intervention: Juice ingestion
Number of subjects: 13
Study 17288066 — intervention group
Group type: EXPERIMENTAL
Intervention: CNO enrollment
Number of subjects: 0
Study 12621096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled (day-night lighted room)
Number of subjects: 40
Study 12621096 — intervention group
Group type: COMPARATOR
Intervention: Dim (dimly lighted room)
Number of subjects: 40
Study 10962113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamp at 10 mmol/l in non-diabetic twins
Number of subjects: 16
Study 10962113 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements in non-diabetic twins
Number of subjects: 16
Study 10962113 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements in diabetic twins
Number of subjects: 16
Study 9068306 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary health education programme
Number of subjects: 1000
Study 9068306 — intervention group
Group type: COMPARATOR
Intervention: Standard health education as delivered by health visitors
Number of subjects: 1000
Study 8392235 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 75
Study 8392235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 75
Study 8392235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 3529352 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 11
Study 3529352 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 11
Study 28752736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic skin disinfection before PNC removal
Number of subjects: 200
Study 28752736 — intervention group
Group type: COMPARATOR
Intervention: Without alcoholic skin disinfection
Number of subjects: 200
Study 28752736 — intervention group
Group type: EXPERIMENTAL
Intervention: With alcoholic skin disinfection
Number of subjects: 200
Study 26215222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocytic infiltration score 3 (LI score 3)
Number of subjects: 195
Study 26215222 — intervention group
Group type: EXPERIMENTAL
Intervention: CD3 staining score 3
Number of subjects: 195
Study 26215222 — intervention group
Group type: EXPERIMENTAL
Intervention: CD20 staining score 3
Number of subjects: 195